Grzegorz SataÅ‚a

List of Publications by Year
in descending order

Version: 2024-02-01

103 papers	1,749 citations	279798 23 h-index	395702 33 g-index
104 all docs	104 docs citations	104 times ranked	1643 citing authors

#	Article	IF	Citations
1	Design and synthesis of new potent 5-HT7 receptor ligands as a candidate for the treatment of central nervous system diseases. European Journal of Medicinal Chemistry, 2022, 227, 113931.	5.5	6
2	An exit beyond the pharmacophore model for 5-HT6R agents - a new strategy to gain dual 5-HT6/5-HT2A action for triazine derivatives with procognitive potential. Bioorganic Chemistry, 2022, 121, 105695.	4.1	8
3	New N-aryl-Nâ€²-aryl-/(thio)ureido-/sulfamoylamino-derivatives of alkyl/alkylcarbamoyl piperazines: Effect of structural modifications on selectivity over 5-HT1A receptor. European Journal of Medicinal Chemistry, 2022, 235, 114319.	5.5	5
4	Overcoming undesirable hERG affinity by incorporating fluorine atoms: A case of MAO-B inhibitors derived from 1ÂH-pyrrolo-[3,2-c]quinolines. European Journal of Medicinal Chemistry, 2022, 236, 114329.	5.5	8
5	Rationally designed N-phenylsulfonylindoles as a tool for the analysis of the non-basic 5-HT6R ligands binding mode. European Journal of Medicinal Chemistry, 2021, 209, 112916.	5.5	2
6	The relationship between stereochemical and both, pharmacological and ADME-Tox, properties of the potent hydantoin 5-HT7R antagonist MF-8. Bioorganic Chemistry, 2021, 106, 104466.	4.1	1
7	Imidazopyridine-Based 5-HT₆ Receptor Neutral Antagonists: Impact of N¹-Benzyl and N¹-Phenylsulfonyl Fragments on Different Receptor Conformational States. Journal of Medicinal Chemistry, 2021, 64, 1180-1196.	6.4	14
8	2-Phenyl-1H-pyrrole-3-carboxamide as a New Scaffold for Developing 5-HT₆ Receptor Inverse Agonists with Cognition-Enhancing Activity. ACS Chemical Neuroscience, 2021, 12, 1228-1240.	3.5	9
9	Multifunctional Ligands with Glycogen Synthase Kinase 3 Inhibitory Activity as a New Direction in Drug Research for Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2021, 28, 1731-1745.	2.4	9
10	Antidepressants Differentially Regulate Intracellular Signaling from Î±1-Adrenergic Receptor Subtypes In Vitro. International Journal of Molecular Sciences, 2021, 22, 4817.	4.1	0
11	Radioligand and computational insight in structure â€“ Activity relationship of saccharin derivatives being ipsapirone and revospirone analogues. Bioorganic and Medicinal Chemistry Letters, 2021, 42, 128028.	2.2	2
12	Design, Sustainable Synthesis and Biological Evaluation of a Novel Dual Î±2A/5-HT7 Receptor Antagonist with Antidepressant-Like Properties. Molecules, 2021, 26, 3828.	3.8	8
13	N-Skatyltryptaminesâ€”Dual 5-HT6R/D2R Ligands with Antipsychotic and Procognitive Potential. Molecules, 2021, 26, 4605.	3.8	3
14	Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands â€“ Fluoxetine and fluvoxamine. European Journal of Medicinal Chemistry, 2021, 220, 113533.	5.5	16
15	A new class of 5-HT1A receptor antagonists with procognitive and antidepressant properties. Future Medicinal Chemistry, 2021, 13, 1497-1514.	2.3	2
16	Design and Synthesis of Novel Aminoalkanamides Targeting Neurodegeneration and Symptoms of Alzheimerâ€™s Disease. Current Medicinal Chemistry, 2021, 28, 6082-6094.	2.4	2
17	Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT₃ and 5-HT₆ Receptor Antagonist with Antipsychotic and Procognitive Properties. Journal of Medicinal Chemistry, 2021, 64, 13279-13298.	6.4	14
18	Neuropathic pain-alleviating activity of novel 5-HT6 receptor inverse agonists derived from 2-aryl-1H-pyrrole-3-carboxamide. Bioorganic Chemistry, 2021, 115, 105218.	4.1	4

#	Article	IF	Citations
19	The Phenoxyalkyltriazine Antagonists for 5-HT6 Receptor with Promising Procognitive and Pharmacokinetic Properties In Vivo in Search for a Novel Therapeutic Approach to Dementia Diseases. International Journal of Molecular Sciences, 2021, 22, 10773.	4.1	11
20	The Structural Determinants for Î±1-Adrenergic/Serotonin Receptors Activity among Phenylpiperazine-Hydantoin Derivatives. Molecules, 2021, 26, 7025.	3.8	4
21	Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties. European Journal of Medicinal Chemistry, 2020, 185, 111857.	5.5	26
22	A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties. European Journal of Medicinal Chemistry, 2020, 208, 112765.	5.5	15
23	Identification of a Potent and Selective 5-HT_{1A} Receptor Agonist with In Vitro and In Vivo Antinociceptive Activity. ACS Chemical Neuroscience, 2020, 11, 4111-4127.	3.5	8
24	Synthesis, crystal structure and biological activity of novel analogues of tricyclic drugs. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127493.	2.2	8
25	Aminotriazines with indole motif as novel, 5-HT7 receptor ligands with atypical binding mode. Bioorganic Chemistry, 2020, 104, 104254.	4.1	7
26	Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors. European Journal of Medicinal Chemistry, 2020, 201, 112420.	5.5	12
27	Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity. European Journal of Medicinal Chemistry, 2020, 201, 112437.	5.5	19
28	Chlorine substituents and linker topology as factors of 5-HT6R activity for novel highly active 1,3,5-triazine derivatives with procognitive properties inÂvivo. European Journal of Medicinal Chemistry, 2020, 203, 112529.	5.5	14
29	Chemical puzzles in the search for new, flexible derivatives of lurasidone as antipsychotic drugs. Bioorganic and Medicinal Chemistry, 2020, 28, 115459.	3.0	9
30	The 1,3,5-Triazine Derivatives as Innovative Chemical Family of 5-HT6 Serotonin Receptor Agents with Therapeutic Perspectives for Cognitive Impairment. International Journal of Molecular Sciences, 2019, 20, 3420.	4.1	43
31	Design, synthesis and biological evaluation of novel serotonin and dopamine receptor ligands being 6-bromohexyl saccharine derivatives. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126667.	2.2	6
32	Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect. European Journal of Medicinal Chemistry, 2019, 183, 111736.	5.5	21
33	Design, synthesis and molecular modelling of new bulky Fananserin derivatives with altered pharmacological profile as potential antidepressants. Bioorganic and Medicinal Chemistry, 2019, 27, 3396-3407.	3.0	12
34	New dual ligands for the D2 and 5-HT1A receptors from the group of 1,8-naphthyl derivatives of LCAP. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2236-2242.	2.2	10
35	Synthesis and computer-aided SAR studies for derivatives of phenoxyalkyl-1,3,5-triazine as the new potent ligands for serotonin receptors 5-HT6. European Journal of Medicinal Chemistry, 2019, 178, 740-751.	5.5	18
36	2-Aminoimidazole-based antagonists of the 5-HT6 receptor â€“ A new concept in aminergic GPCR ligand design. European Journal of Medicinal Chemistry, 2019, 179, 1-15.	5.5	20

#	Article	IF	Citations
37	Dual 5-HT₆ and D₃ Receptor Antagonists in a Group of 1H-Pyrrolo[3,2-c]quinolines with Neuroprotective and Procognitive Activity. ACS Chemical Neuroscience, 2019, 10, 3183-3196.	3.5	24
38	Fluorinated indole-imidazole conjugates: Selective orally bioavailable 5-HT7 receptor low-basicity agonists, potential neuropathic painkillers. European Journal of Medicinal Chemistry, 2019, 170, 261-275.	5.5	22
39	Synthesis and computer-aided analysis of the role of linker for novel ligands of the 5-HT6 serotonin receptor among substituted 1,3,5-triazinylpiperazines. Bioorganic Chemistry, 2019, 84, 319-325.	4.1	13
40	Discovery and Development of Non-Dopaminergic Agents for the Treatment of Schizophrenia: Overview of the Preclinical and Early Clinical Studies. Current Medicinal Chemistry, 2019, 26, 4885-4913.	2.4	7
41	Structural insights into serotonin receptor ligands polypharmacology. European Journal of Medicinal Chemistry, 2018, 151, 797-814.	5.5	7
42	Novel naphthyloxy derivatives â€“ Potent histamine H3 receptor ligands. Synthesis and pharmacological evaluation. Bioorganic and Medicinal Chemistry, 2018, 26, 2573-2585.	3.0	24
43	Computer-aided insights into receptor-ligand interaction for novel 5-arylhydantoin derivatives as serotonin 5-HT 7 receptor agents with antidepressant activity. European Journal of Medicinal Chemistry, 2018, 147, 102-114.	5.5	16
44	Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects. European Journal of Medicinal Chemistry, 2018, 145, 790-804.	5.5	43
45	Allosteric Inhibition of Serotonin 5-HT7 Receptors by Zinc Ions. Molecular Neurobiology, 2018, 55, 2897-2910.	4.0	13
46	Novel non-sulfonamide 5-HT 6 receptor partial inverse agonist in a group of imidazo[4,5- b]pyridines with cognition enhancing properties. European Journal of Medicinal Chemistry, 2018, 144, 716-729.	5.5	37
47	Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT6 Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo. Molecules, 2018, 23, 2529.	3.8	18
48	Amino Acid Hot Spots of Halogen Bonding: A Combined Theoretical and Experimental Case Study of the 5-HT₇ Receptor. Journal of Medicinal Chemistry, 2018, 61, 8717-8733.	6.4	28
49	Pyrroloquinoline scaffold-based 5-HT6R ligands: Synthesis, quantum chemical and molecular dynamic studies, and influence of nitrogen atom position in the scaffold on affinity. Bioorganic and Medicinal Chemistry, 2018, 26, 3588-3595.	3.0	15
50	The effect of the intramolecular Câ€“Hâ‹¯O interactions on the conformational preferences of bis-arylsulfones â€“ 5-HT₆ receptor antagonists and beyond. RSC Advances, 2018, 8, 18672-18681.	3.6	11
51	The role of aryl-topology in balancing between selective and dual 5-HT₇R/5-HT_{1A}actions of 3,5-substituted hydantoins. MedChemComm, 2018, 9, 1033-1044.	3.4	7
52	Structural determinants influencing halogen bonding: a case study on azinesulfonamide analogs of aripiprazole as 5-HT1A, 5-HT7, and D2 receptor ligands. Chemistry Central Journal, 2018, 12, 55.	2.6	8
53	Spiro[pyrrolidine-3,3â€²-oxindoles] as 5-HT 7 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2418-2421.	2.2	11
54	From Homology Models to a Set of Predictive Binding Pocketsâ€“a 5-HT_{1A} Receptor Case Study. Journal of Chemical Information and Modeling, 2017, 57, 311-321.	5.4	23

#	Article	IF	Citations
55	Novel 5-HT 7 R antagonists, arylsulfonamide derivatives of (aryloxy)propyl piperidines: Add-on effect to the antidepressant activity of SSRI and DRI, and pro-cognitive profile. Bioorganic and Medicinal Chemistry, 2017, 25, 2789-2799.	3.0	18
56	The computer-aided discovery of novel family of the 5-HT6 serotonin receptor ligands among derivatives of 4-benzyl-1,3,5-triazine. European Journal of Medicinal Chemistry, 2017, 135, 117-124.	5.5	33
57	Design, Synthesis and Biological Evaluation of Potent Antioxidant 1â€(2,5â€Dimethoxybenzyl)â€4â€arylpiperazines and Nâ€Azolyl Substituted 2â€(4â€Arylpiperazinâ€1â€yl) ChemistrySelect, 2017, 2, 3854-3859.	1.5	4
58	The impact of the halogen bonding on D 2 and 5-HT 1A /5-HT 7 receptor activity of azinesulfonamides of 4-[(2-ethyl)piperidinyl-1-yl]phenylpiperazines with antipsychotic and antidepressant properties. Bioorganic and Medicinal Chemistry, 2017, 25, 3638-3648.	3.0	24
59	Low-basicity 5-HT7 Receptor Agonists Synthesized Using the van Leusen Multicomponent Protocol. Scientific Reports, 2017, 7, 1444.	3.3	18
60	Pyrano[2,3,4-cd]indole as a Scaffold for Selective Nonbasic 5-HT₆R Ligands. ACS Medicinal Chemistry Letters, 2017, 8, 390-394.	2.8	8
61	The Effect of Carboxamide/Sulfonamide Replacement in Arylpiperazinylalkyl Derivatives on Activity to Serotonin and Dopamine Receptors. Archiv Der Pharmazie, 2017, 350, 1700090.	4.1	5
62	In the search for a lead structure among series of potent and selective hydantoin 5â€<scp>HT</scp>₇R agents: The drugâ€likeness in vitro study. Chemical Biology and Drug Design, 2017, 90, 1295-1306.	3.2	41
63	Synthesis and Structure-Activity Relationship Analysis of 5-HT7 Receptor Antagonists: Piperazin-1-yl Substituted Unfused Heterobiaryls. Molecules, 2016, 21, 433.	3.8	5
64	Halogen bonding enhances activity in a series of dual 5-HT₆/D₂ ligands designed in a hybrid bioisostere generation/virtual screening protocol. RSC Advances, 2016, 6, 54918-54925.	3.6	6
65	Structural modifications of the serotonin 5-HT7 receptor agonist N-(4-cyanophenylmethyl)-4-(2-biphenyl)-1-piperazinehexanamide (LP-211) to improve inÂvitro microsomal stability: A case study. European Journal of Medicinal Chemistry, 2016, 120, 363-379.	5.5	14
66	Rational design in search for 5-phenylhydantoin selective 5-HT7R antagonists. Molecular modeling, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2016, 112, 258-269.	5.5	21
67	N1-Azinylsulfonyl-1H-indoles: 5-HT6 Receptor Antagonists with Procognitive and Antidepressant-Like Properties. ACS Medicinal Chemistry Letters, 2016, 7, 618-622.	2.8	42
68	Novel 1H-Pyrrolo[3,2-c]quinoline Based 5-HT₆ Receptor Antagonists with Potential Application for the Treatment of Cognitive Disorders Associated with Alzheimerâ€™s Disease. ACS Chemical Neuroscience, 2016, 7, 972-983.	3.5	64
69	Structureâ€“5â€HT/D₂ Receptor Affinity Relationship in a New Group of 1â€Arylpiperazynylalkyl Derivatives of 8â€Dialkylaminoâ€3,7â€dimethylâ€1Hâ€purineâ€2,6(3H,7H)â€dione. Archiv Der Pharmazie, 2016, 349, 774-784.	4.1	2
70	Towards new 5-HT 7 antagonists among arylsulfonamide derivatives of (aryloxy)ethyl-alkyl amines: Multiobjective based design, synthesis, and antidepressant and anxiolytic properties. European Journal of Medicinal Chemistry, 2016, 108, 334-346.	5.5	28
71	Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action. Pharmacology Biochemistry and Behavior, 2016, 141, 28-41.	2.9	17
72	Concentration-Dependent Dual Mode of Zn Action at Serotonin 5-HT1A Receptors: In Vitro and In Vivo Studies. Molecular Neurobiology, 2016, 53, 6869-6881.	4.0	30

#	Article	IF	Citations
73	N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT7 receptor selectivity versus multireceptor profile. Bioorganic and Medicinal Chemistry, 2016, 24, 130-139.	3.0	16
74	Arylpiperazinylalkyl derivatives of 8-amino-1,3-dimethylpurine-2,6-dione as novel multitarget 5-HT/D receptor agents with potential antipsychotic activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 2016, 31, 1048-1062.	5.2	10
75	Solidâ€Supported Synthesis and 5â€<scp>HT</scp>₇/5â€<scp>HT</scp>_{1A} Receptor Affinity of Arylpiperazinylbutyl Derivatives of 4,5â€dihydroâ€1,2,4â€triazineâ€6â€(1H)â€one. Chemical Biology and Drug Design, 2015, 86, 697-703.	3.0	7
76	Synthesis of Some Aminophosphonates Bearing Nâ€(Fluorophenyl)â€piperazynyl Moiety and Their Activity toward Serotonin Receptors. Heteroatom Chemistry, 2015, 26, 290-298.	0.7	2
77	Rational design of 5-HT6R ligands using a bioisosteric strategy: synthesis, biological evaluation and molecular modelling. RSC Advances, 2015, 5, 25806-25815.	3.6	10
78	Arylsulfonamide derivatives of (aryloxy)ethylpiperidines as selective 5-HT₇ receptor antagonists and their psychotropic properties. MedChemComm, 2015, 6, 1272-1277.	3.4	13
79	New Arylpiperazinylalkyl Derivatives of 8â€Alkoxyâ€purineâ€2,6â€dione and Dihydro[1,3]oxazolo[2,3â€f]purinedione Targeting the Serotonin 5â€HT_{1A}/5â€HT_{2A}/5â€HT₇ and Dopamine D₂ Receptors. Archiv Der Pharmazie, 2015, 348, 242-253.	4.1	6
80	Towards novel 5-HT7 versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: Design, synthesis, and antidepressant properties. Part II. European Journal of Medicinal Chemistry, 2015, 92, 202-211.	5.5	16
81	N-(4-Arylpiperazinoalkyl)acetamide derivatives of 1,3- and 3,7-dimethyl-1H-purine-2,6(3H,7H)-diones and their 5-HT₆, 5-HT₇, and D₂ receptors affinity. Heterocyclic Communications, 2015, 21, 13-18.	1.2	6
82	Synthesis and Evaluation of Antidepressantâ€like Activity of Some 4â€Substituted 1â€(2â€methoxyphenyl)Piperazine Derivatives. Chemical Biology and Drug Design, 2015, 85, 326-335.	3.2	50
83	Structureâ€“activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2,4-diones and purine-2,4,8-triones with antidepressant and anxiolytic-like activity. European Journal of Medicinal Chemistry, 2015, 97, 142-154.	5.5	27
84	Fingerprint-based consensus virtual screening towards structurally new 5-HT6R ligands. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1827-1830.	2.2	16
85	Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 5. European Journal of Medicinal Chemistry, 2015, 98, 221-236.	5.5	16
86	Rational Design, Pharmacomodulation, and Synthesis of Dual 5-Hydroxytryptamine 7 (5-HT₇)/5-Hydroxytryptamine 2A (5-HT_{2A}) Receptor Antagonists and Evaluation by [¹⁸F]-PET Imaging in a Primate Brain. Journal of Medicinal Chemistry, 2015, 58, 8066-8096.	6.4	15
87	Antidepressant- and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1,3-dimethyl-purine-2,6-dione derivatives with diversified 5-HT1A receptor functional profile. Bioorganic and Medicinal Chemistry, 2015, 23, 212-221.	3.0	31
88	New 1-arylindoles based serotonin 5-HT7 antagonists. Synthesis andÂbinding evaluation studies. European Journal of Medicinal Chemistry, 2014, 75, 159-168.	5.5	14
89	SAR-studies on the importance of aromatic ring topologies in search for selective 5-HT7 receptor ligands among phenylpiperazine hydantoin derivatives. European Journal of Medicinal Chemistry, 2014, 78, 324-339.	5.5	36
90	Solid-supported synthesis, molecular modeling, and biological activity of long-chain arylpiperazine derivatives with cyclic amino acid amide fragments as 5-HT7 and 5-HT1A receptor ligands. European Journal of Medicinal Chemistry, 2014, 78, 10-22.	5.5	23

#	Article	IF	Citations
91	New 7-arylpiperazinylalkyl-8-morpholin-4-yl-purine-2,6-dione derivatives with anxiolytic activity â€“ Synthesis, crystal structure and structureâ€“activity study. Journal of Molecular Structure, 2014, 1067, 243-251.	3.6	10
92	Antidepressant and antipsychotic activity of new quinoline- and isoquinoline-sulfonamide analogs of aripiprazole targeting serotonin 5-HT1A/5-HT2A/5-HT7 and dopamine D2/D3 receptors. European Journal of Medicinal Chemistry, 2013, 60, 42-50.	5.5	81
93	New 8-aminoalkyl derivatives of purine-2,6-dione with arylalkyl, allyl or propynyl substituents in position 7, their 5-HT1A, 5-HT2A, and 5-HT7 receptor affinity and pharmacological evaluation. Pharmacological Reports, 2013, 65, 15-29.	3.3	15
94	Synthesis and evaluation of pharmacological properties of some new xanthone derivatives with piperazine moiety. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4419-4423.	2.2	35
95	Towards metabolically stable 5-HT7 receptor ligands: a study on 1-arylpiperazine derivatives and related isosters. Experimental Brain Research, 2013, 230, 569-582.	1.5	14
96	Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives asÂpotential antidepressant agents. Part 1. European Journal of Medicinal Chemistry, 2013, 63, 484-500.	5.5	33
97	Quinolinesulfonamides of Aryloxyâ€/Arylthioâ€ethyl Piperidines: Influence of an Arylether Fragment on 5â€HT_{1A}/5â€HT₇ Receptor Selectivity. Archiv Der Pharmazie, 2013, 346, 180-188.	4.1	4
98	Synthesis, anticonvulsant activity and 5-HT1A/5-HT7 receptors affinity of 1-[(4-arylpiperazin-1-yl)-propyl]-succinimides. Pharmacological Reports, 2012, 64, 326-335.	3.3	11
99	The multiobjective based design, synthesis and evaluation of the arylsulfonamide/amide derivatives of aryloxyethyl- and arylthioethyl- piperidines and pyrrolidines as a novel class of potent 5-HT7 receptor antagonists. European Journal of Medicinal Chemistry, 2012, 56, 348-360.	5.5	35
100	Acute and repeated treatment with the 5-HT7 receptor antagonist SB 269970 induces functional desensitization of 5-HT7 receptors in rat hippocampus. Pharmacological Reports, 2012, 64, 256-265.	3.3	20
101	Quinoline- and isoquinoline-sulfonamide derivatives of LCAP as potent CNS multi-receptorâ€”5-HT1A/5-HT2A/5-HT7 and D2/D3/D4â€”agents: The synthesis and pharmacological evaluation. Bioorganic and Medicinal Chemistry, 2012, 20, 1545-1556.	3.0	59
102	Solid-Phase Synthesis of Arylpiperazine Derivatives and Implementation of the Distributed Drug Discovery (D3) Project in the Search for CNS Agents. Molecules, 2011, 16, 4104-4121.	3.8	2
103	Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands. Bioorganic and Medicinal Chemistry, 2011, 19, 6750-6759.	3.0	33